Biotechnology Crispr Therapeutics makes significantly higher loss in the second quarter

The Zug-based biotech company Crispr Therapeutics, which is listed on the Nasdaq, closed the second quarter of 2024 with deep red figures.

Keystone-SDA

05.08.2024, 22:39

SDA

In a statement, Crispr put the quarterly loss at 126.4 million US dollars. In the previous year, however, it was only 77.7 million dollars.

Sales in the same period amounted to 70.0 million Swiss francs. The turnover was mainly due to payments resulting from the achievement of research milestones.

Cash and cash equivalents amounted to around USD 2.0 billion at the end of June 2024, compared to just under USD 1.7 billion at the end of 2023. The increase in cash was due to a direct issue and milestone payments from Vertex in connection with the approval of CASGEVY, it added.